Recently, the Ministry of Agriculture and Rural Affairs issued No. 847 announcement, stating that the "Porcine Pseudorabies Live Vaccine (JS-A1 Strain)" developed by the Prevention and Control of Porcine Viral Reproductive Disorder Disease Team of SHVRI, in collaboration with Chengdu SG-Biotech Co., Ltd. and Shenlian Biomedical (Shanghai) Co., Ltd. has been approved for the national Class III New Veterinary Drug Registration Certificate.

Pseudorabies is an acute, severe, and highly lethal infectious disease caused by pseudorabies virus (PRV). Emerging variants of PRV have evaded the antiviral immunity of commercially available vaccine and led to PRV outbreaks in Chinese pig farms, causing severe economic losses. The high-temperature passaging attenuated pseudorabies vaccine (JS-A1 strain) is safe and effective, and piglets or sows that have been immunized can fully resist attacks from PRV variants and classical virulent strains. This vaccine solves the clinical problem that commercial vaccines cannot provide complete protection. The appearance of the product will strongly support the prevention and control of PRV variants, and greatly promote the cleanse of pseudorabies in China.

The product was funded by the Innovation Program of CAAS, the National Key Research and Development Program of China, Shanghai Municipal Agriculture Science and Technology Key Project, and Shanghai Science and Technology Innovation Action Plan.